M4 acute myeloid leukemia: The role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience

Haematologica

Volumn 93, Issue 7, 2008, Pages 1025-1032

  Pulsoni, Alessandro ^a   Lacobelli, Simona ^b   Bernardi, Massimo ^c   Borgia, Marco ^d   Camera, Andrea ^e   Cantore, Nicola ^f   Raimondo, Francesco Di ^g   Fazi, Paola ^b   Ferrara, Felicetto ^h   Leoni, Franco ⁱ   Liso, Vincenzo ^j   Mancini, Marco ^a   Marmont, Filippo ^k   Matturro, Angela ^a   Maurillo, Luca ^l   Melillo, Lorella ^m   Meloni, Giovanna ^a   Mirto, Salvo ⁿ   Specchia, Giorgina ^o   Valentini, Caterina Giovanna ^p   Venditti, Adriano ^q   Leone, Giuseppe ^p   Foà, Robin ^a   Mandelli, Franco ^a   Pagano, Livio ^p   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Data Center   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Division of Hematology

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f S G MOSCATI HOSPITAL   (Italy)

^g Divlsion of Hematology

^h CARDARELLI HOSPITAL   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j Division of Hematology   (Italy)

^k MOLINETTE HOSPITAL   (Italy)

^l S EUGENIO HOSPITAL   (Italy)

^m CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁿ VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^o Division of Hematology

^p CATHOLIC UNIVERSITY   (Italy)

^q UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Eosinophilia; Inv(16).; M4 AML; Myelo monoeytic acute leukemia

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME INVERSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; EOSINOPHILIA; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; COMBINED MODALITY THERAPY; CYTOGENETICS; DISEASE-FREE SURVIVAL; EOSINOPHILIA; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 46849086977     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11889     Document Type: Article

References (27)

1. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986;68: 1242-9.
2. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med 1983;309:630-6.
3. Loffler H, Gassmann W, Haferlach T. AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects. Leuk Lymphoma 1995;18 (Suppl 1):61-3.
4. Monahan BP, Rector JT, Liu PP, Cotelingam JD, Dahut W. Clinical aspects of expression of inversion 16 chromosomal fusion transcript CBFB/MYH11 in acute myelogenous leukemia subtype M1 with abnormal bone marrow eosinophilia. Leukemia 1996;10:1653-75.
5. Haferlach T, Winkemann M, Loffler H, Schoch R, Gassmann W, Fonatsch C, et al. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May- Grünwald-Giemsa staining and fluorescence in situ hybridization. Blood 1996;87:2459-63.
6. Hernandez JM, Gonzàlez BN, Granata I, Gutiérrez N, Chillón C, Ramos F, et al. Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo. Haematologica 2000;85:481-5.
7. Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 2005;106:1369-75.
8. Egan N, O'Reilly J, Clipper L, Higgins M, Herrmann R, Cannell P. Detection of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16. Cancer Genet Cytogenet 2004;154:60-2.
9. Reilly JT. Pathogenesis of acute myeloid leukemia and inv(16) (p13;q22): a paradigm for understanding leukaemogenesis. Br J Haematol 2004;128:18-34.
10. Kundu M, Chen A, Anderson S, Kirby M, Xu L, Castilla LH, et al. Role of CBFβ in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene CBFβ-MYH11. Blood 2002;100:2449-56.
11. Merchant SH, Haines S, Hall B, Hozier J, Viswanatha DS. Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo. J Mol Diagn 2004;6: 271-4.
12. Sun X, Medeiros J, Rassidakis GZ, Bueso-Ramos C. Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22). Am J Clin Pathol 2003;120:236-45.
13. Aventìn A, Espadadel M, Casa S, Duarte J, Nomdedéu J, Sierra J. Chromosome 16 inversion-associated translocations in acute myeloid leukemia elucidated using a dual-color CBFB DNA probe. Cancer Genet Cytogenet 2002; 134:142-4.
14. Bloomfiel CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9.
15. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuousinfusion high-dose cytosine arabinoside. Leukemia 1994;8:1269-74.
16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial. Blood 1998;92:2322-33.
17. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312-20.
18. Byrd JC, Mròzek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100: 4325-36.
19. Plantier I, Lai JL, Wattel E, Bauters F, Fenaux P. Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res 1994;18:885-8.
20. Razzouk BI, Raimondi SC, Srivastava DK, Pritchard M, Behm FG, Tong X, et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia 2001;15:1326-30.
21. Vignetti M, De Witte TM, Suciu S, Zittoun R, Resegotti L, Liso V, et al. Daunorubicin (DNR) vs. mitoxantrone (MTZ) vs. idarubicin (IDA) administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem transplantation (SCT): results of the EORTC-GIMEMA. Blood 2003; 102[Abstract 611].
22. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. The GIMEMA Acute Leukemia Working Party. N Engl J Med 2005;352:254-66.
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American- British Cooperative Group. Ann Intern Med 1985;103:620-5.
24. Byrd JC, Ruppert AS, Mròzek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004; 22:1087-94.
25. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 2006;24:3904-11.
26. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463-8.
27. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired eventfree and overall survival. Blood 2006;107:1791-9.